Evidence map›Paper›PMID 21079871›Full record

ArticleChemical communications (Cambridge, England)2011

Ribonuclease S redux.

Rex W Watkins, Ulrich Arnold, Ronald T Raines

Abstract read
In one paragraph

Article in Chemical communications (Cambridge, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Semisynthesis of Human Ribonuclease-S.Bioconjugate chemistry · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rex W WatkinsDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706-1544, USA.
Ulrich Arnold
Ronald T Raines

Funding

Chemistry-Biology Interface Training ProgramT32GM008505 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BLACKWELL, HELEN E. · 1993 to 2023
$9.8M
RIBONUCLEASES IN CANCER THERAPYR01CA073808 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAINES, RONALD T · 1997 to 2024
$7.3M
STRUCTURE--FUNCTION ANALYSIS OF RIBONUCLEASE AR01GM044783 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI RAINES, RONALD T · 1990 to 2021
$7.1M
NCI NIH HHS R01 CA073808NIGMS NIH HHS R01 GM044783NIGMS NIH HHS T32 GM008505
6 · The paper itself

Abstract

The S-peptide and S-protein components of bovine pancreatic ribonuclease form a noncovalent complex with restored ribonucleolytic activity. Although this archetypal protein-fragment complementation system has been the object of historic work in protein chemistry, intrinsic limitations compromise its utility. Modern methods are shown to overcome those limitations and enable new applications.

Indexed as

AnimalsBacillus subtilisCattleDexfenfluramineModels, MolecularPeptide FragmentsProtein ConformationRibonuclease, PancreaticSubtilisinDexfenfluraminePeptide FragmentsRibonuclease, PancreaticSubtilisin

Identifiers

PMID21079871
PMCPMC3077719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.